HLS Therapeutics (TSX:HLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $12.864 million which missed the analyst consensus estimate of $13.033 million by 1.30 percent. This is a 1.91 percent increase over sales of $12.623 million the same period last year.